Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.

Chunsheng WangKewei ZhaoShanliang HuWei DongYan Gong Conghua Xie

Published in: The oncologist (2023)

Both afatinib and osimertinib displayed favorable clinical activities toward uncommon EGFR mutations. Afatinib showed a more profound and durable PFS benefit than osimertinib, although no efficacy advantage was observed.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
small cell lung cancer
intellectual disability
autism spectrum disorder